References
Anand BS. Drug treatment of the complications of cirrhosis in the older adult. Drugs & Aging 2001; 18(8): 575–85
Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998; 27: 264–72
Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701–7
Lake JR. The role of transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1745–7
Runyon BA, McHutchinson JG, Antillon MR, et al. Short-course versus long course antibiotic treatment of spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 1737–42
Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403–9
Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12: 716–24
Bernard B, Grange JD, Nguyen Khac E, et al. Antibiotic prophylaxis for prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 1998; 59 Suppl. 2: 54–7
Westaby D, Hayes P, Gimson AE, et al. Controlled trial of injection sclerotherapy for active variceal bleeding. Hepatology 1989; 9: 274–7
D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332–54
Sarin SK, Lamba GS, Kumar M, et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999; 340: 988–93
Conn HO. Animal versus vegetable protein diet in hepatic encephalopathy. J Intern Med 1993; 233: 369–71
Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1691–7
Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870–5
Guevara M, Gines P, Bandi JC, et al. Transjugular portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416–2
Rights and permissions
About this article
Cite this article
A multi-pronged approach required for management of complications of cirrhosis of the liver. Drugs Ther. Perspect 18, 8–11 (2002). https://doi.org/10.2165/00042310-200218060-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200218060-00003